Korean medical imaging software startup FlONICS has secured seed funding from Kakao Ventures, Digital Healthcare Partners (DHP), and Kangwon National University Holdings.

FlONICS is developing “Flonics-Streamliner,” a software solution that visualizes and analyzes blood flow dynamics in three dimensions over time. By analyzing hemodynamic data—including flow patterns, velocity, and direction within the heart and vessels—the software supports comprehensive diagnosis, treatment planning, and prognosis evaluation for cardiovascular and cerebrovascular diseases. Unlike conventional methods that merely interpret static vascular morphology, FlONICS leverages 4D Flow MRI technology to capture the dynamic, time-varying nature of blood flow, allowing detection of subtle pathological changes that were previously difficult to identify.

Cardiovascular diseases remain the leading cause of death worldwide, requiring accurate early diagnosis and sophisticated analysis. Traditional imaging methods provide only fragmented morphological information and often involve complex, inconvenient workflows. FlONICS addresses these limitations with a highly accurate, non-invasive solution capable of completing blood flow analysis in just 30 minutes. The software was developed in close collaboration with clinicians, ensuring an optimized user experience that significantly improves clinical efficiency and usability.

FlONICS’s founding team brings exceptional expertise to the field. CEO Hojin Ha, a professor of Biomedical and Mechatronics Engineering at Kangwon National University, is a leading authority in hemodynamics. He is joined by Donghyun Yang, a professor of Radiology at Asan Medical Center, and specialists in medical image processing and medical AI. The team is recognized for its unmatched capabilities in translating real-world clinical insights and patient data into advanced flow analysis and therapeutic models. Prior to this funding, FlONICS had successfully executed multiple government-backed R&D projects, including the Ministry of Science and ICT’s Deep Science Startup Activation Program, validating both its technological strength and business potential.

With this investment, FlONICS plans to complete prototype development within the year while advancing technical sophistication. In parallel, it will validate clinical efficacy and expand collaborations with domestic and international institutions such as Asan Medical Center. The company intends to introduce a usage-based pricing model, providing hospitals and research institutions with a cost-efficient alternative. By next year, FlONICS aims to secure domestic regulatory approvals and enter the global market.

Juyeon Jeong, Senior Associate at Kakao Ventures, who led the investment, stated:
“FlONICS combines world-class hemodynamic analysis capabilities with medical AI expertise, positioning itself to pioneer the clinical application of 4D Flow MRI. We will continue to support the company as it scales to become a transformative solution in cardiovascular diagnostics.”

Hojin Ha, CEO of FlONICS, added “Our goal is to successfully commercialize FlONICS’s innovative technology to deliver tangible improvements for both clinicians and patients. We aspire to establish the global standard solution that physicians worldwide trust first for the diagnosis and treatment of cardiovascular disease.”